

*B*  
*cont*

79. A pharmaceutical composition comprising the TNF inhibitor encoded by the nucleic acid of Claim 77.

80. A recombinant DNA expression vector comprising a nucleic acid sequence of Claim 76.

81. A recombinant host cell comprising the expression vector of Claim 80.

82. A recombinant host cell of Claim 81 wherein said cell is a eukaryote or a prokaryote.

---

**REMARKS**

Reconsideration of this application, as amended, is respectfully requested.

Claims 25-75 were pending in this application, and have been cancelled without prejudice. New claims 76-82 have been added. The Applicants contend that no new matter has been added as a result of the above-described amendments. The subject matter of claims 76-77 is described at, for example, page 70 of the originally filed application. Similarly, the subject matter of claims 78-79 is described at, for example, page 38, lines 1-12. And, the subject matter of claims 80-82 is described at page 19, line 30 to page 26, line 37. With entry of this amendment, the currently pending claims are 76-82.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

By:

  
\_\_\_\_\_  
Kevin E. Noonan, Ph.D.  
Reg. No. 35,303

Date: 08/12/99